AccessMyLibrary provides FREE access to over 30 million articles from top publications available through your library.
Create a link to this page
Copy and paste this link tag into your Web page or blog:
2002 MAY 22 - (NewsRx.com & NewsRx.net) -- ID Biomedical Corp. announced that it has been granted permission by the Biologics and Genetic Therapies Directorate of the Health Products and Foods Branch of Health Canada to conduct a phase II clinical trial of StreptAvax, ID Biomedical's vaccine for the prevention of infections caused by group A streptococcus. StreptAvax is the only vaccine of its kind being tested in human clinical trials.
Permission was granted based on results from the phase I clinical trial which showed that StreptAvax had a good safety profile and was well tolerated by healthy adult volunteers. Additionally, the phase I study showed that StreptAvax stimulated broad immune responses against the strains targeted by the vaccine.
StreptAvax is a multivalent recombinant vaccine developed to cover 26 serotypes of group A streptococcus. According to data obtained from the U.S. Centers for Disease Control and Prevention (CDC), these serotypes are believed to be responsible for causing the vast majority of ...